He Q, Wang M, Zhu H, Xiao Y, Wen R, Liu X
Front Aging Neurosci. 2024; 16:1450863.
PMID: 39280700
PMC: 11392875.
DOI: 10.3389/fnagi.2024.1450863.
Wang Y, Zhang S, Zhang F, Wang L, Wu C, Zhang X
Front Oncol. 2023; 13:1155019.
PMID: 37207161
PMC: 10189879.
DOI: 10.3389/fonc.2023.1155019.
Tomela K, Pietrzak B, Galus L, Mackiewicz J, Schmidt M, Mackiewicz A
Cells. 2023; 12(5).
PMID: 36899926
PMC: 10000540.
DOI: 10.3390/cells12050789.
Sipahioglu H, Onuk S
Medicine (Baltimore). 2022; 101(38):e30759.
PMID: 36197158
PMC: 9508955.
DOI: 10.1097/MD.0000000000030759.
Sun Q, Sun H, Wu N, Hu Y, Zhang F, Cong X
Front Oncol. 2022; 12:976224.
PMID: 36185176
PMC: 9515964.
DOI: 10.3389/fonc.2022.976224.
Case Report: First-Line Immunotherapy for Esophageal Squamous Carcinoma Combined With Hypopharyngeal Squamous Carcinoma Yields Sustained Survival Benefit.
Yang Y, Liu X, Song W, Lu J, Yin N, Ye X
Front Immunol. 2022; 13:907705.
PMID: 35898511
PMC: 9311332.
DOI: 10.3389/fimmu.2022.907705.
Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma.
Aroldi F, Middleton M
Am J Clin Dermatol. 2022; 23(3):331-338.
PMID: 35359259
DOI: 10.1007/s40257-022-00681-4.
Not-so-opposite ends of the spectrum: CD8 T cell dysfunction across chronic infection, cancer and autoimmunity.
Collier J, Weiss S, Pauken K, Sen D, Sharpe A
Nat Immunol. 2021; 22(7):809-819.
PMID: 34140679
PMC: 9197228.
DOI: 10.1038/s41590-021-00949-7.
Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes.
Mesti T, Ceplak Mencin V, Boshkoska B, Ocvirk J
Radiol Oncol. 2021; 55(3):354-361.
PMID: 33939899
PMC: 8366732.
DOI: 10.2478/raon-2021-0019.
Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis.
Fan Y, Xie W, Huang H, Wang Y, Li G, Geng Y
Front Oncol. 2021; 11:633032.
PMID: 33912454
PMC: 8072154.
DOI: 10.3389/fonc.2021.633032.
Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial.
Grabbe P, Gschwendtner K, Maatouk I, Strobel S, Salzmann M, Bossert J
Trials. 2021; 22(1):294.
PMID: 33879219
PMC: 8056554.
DOI: 10.1186/s13063-021-05234-4.
Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors.
Zhong L, Wu Q, Chen F, Liu J, Xie X
Cancer Immunol Immunother. 2021; 70(9):2559-2576.
PMID: 33576872
PMC: 10991616.
DOI: 10.1007/s00262-020-02803-5.
The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients.
Tomela K, Pietrzak B, Schmidt M, Mackiewicz A
Life (Basel). 2020; 10(10).
PMID: 32992737
PMC: 7600343.
DOI: 10.3390/life10100219.
Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study.
Han Y, Zhang H, Mu S, Wei W, Jin C, Tong C
Aging (Albany NY). 2020; 12(12):11245-11258.
PMID: 32633729
PMC: 7343511.
DOI: 10.18632/aging.103372.
Immune metabolism in PD-1 blockade-based cancer immunotherapy.
Kumar A, Chamoto K
Int Immunol. 2020; 33(1):17-26.
PMID: 32622347
PMC: 7771015.
DOI: 10.1093/intimm/dxaa046.
Prognostic and predictive factors associated with ipilimumab-related adverse events: a retrospective analysis of 11 NCI-sponsored phase I clinical trials.
Chauhan A, Kabir T, Wu J, Wei J, Cook M, Kunos C
Oncotarget. 2020; 11(16):1427-1434.
PMID: 32363000
PMC: 7185063.
DOI: 10.18632/oncotarget.27537.
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers.
Tai D, Choo S, Chew V
Cancers (Basel). 2019; 11(12).
PMID: 31816940
PMC: 6966558.
DOI: 10.3390/cancers11121926.
Targeting L-Lactate Metabolism to Overcome Resistance to Immune Therapy of Melanoma and Other Tumor Entities.
Feichtinger R, Lang R
J Oncol. 2019; 2019:2084195.
PMID: 31781212
PMC: 6875281.
DOI: 10.1155/2019/2084195.
Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control.
Hughes M, Zheng H, Zubiri L, Molina G, Chen S, Mooradian M
Cancer Med. 2019; 8(11):4986-4999.
PMID: 31286682
PMC: 6718531.
DOI: 10.1002/cam4.2397.
Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches.
Motofei I
Curr Treat Options Oncol. 2019; 20(6):45.
PMID: 31056729
DOI: 10.1007/s11864-019-0643-4.